The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...

(RTTNews) - InflaRx N.V. (IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, announced on Wednesday that the European Commission or EC has granted marketing ...

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and ...

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% ...

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 price ...

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR.